The present disclosure is in the field of gastric resident systems. A device for extended retention in a stomach is provided. The device includes: first, second, and third arms, the second and third arms being pivotally connected to respective ends of the first arm. The device is configured to transform between a compressed configuration and an expanded configuration. The device further includes a biasing member configured to bias the device into the expanded configuration whereby the second and third arms are configured to mechanically engage each other to retain the system in the expanded configuration.

The present invention relates generally to the field of protease-responsive drug delivery hydrogels, uses thereof, and related methods of their production. More particularly, the invention relates to hydrogels which release anti-inflammatory agents upon reaction with inflammation-related proteases.

The present invention provides a composition comprising a polymer and a natural or synthetic peptide or protein (NSPP). The composition forms a hydrogel with water. The composition is useful as a filler for cosmetic and therapeutic applications. Embodiments of the invention provide methods of treating certain conditions using the composition or hydrogel, and surgical kits for the simultaneous or sequential administration of the respective components of the composition, enabling the formation of the hydrogel in situ.

Methods of forming, dissolving, and functionalizing an extracellular matrix gel on demand based on cross-linking, modification, and dissolution of hydrogels using transpeptidase (e.g. sortase) are disclosed. Also provided are hydrogels comprising one or more macromers crosslinked to a mixture of peptides, wherein all or a portion of the peptides in the mixture comprise a recognition motif cleavable by a transpeptidase (e.g., sortase).

The invention relates to a method for the stabilization of a polysaccharide (hyaluronic acid) with a biomolecule—amino acid—through crosslinking, to generate a bionic hydrogel based on physiological building blocks for applications in regenerative medicine. The designed biosimilar hydrogel is intended to be used in regenerative medicine for the purpose of regenerate, rejuvenate and/or restore the structure or function of impaired or damaged tissues, and to promote healing. The manufacture method is composed of a single step that includes mixing L-lysine and hyaluronic acid sodium salt in an aqueous saline solution with either EDC/NHS as coupling agent.

The present invention provides a nanogel nasal vaccine that induces cell-mediated immunity. The present invention relates to a vaccine preparation comprising a complex of a nanogel, a vaccine antigen, and an adjuvant, wherein the vaccine preparation can efficiently induce the cell-mediated immunity, and can also induce a systemic and mucosal immune response.

The invention provides a composition and pharmaceutical formulation including a peptide immobilized in a hydrogel. Compositions and formulations of the invention are useful in reducing the size, severity or duration of a wound, ameliorating of one or more symptoms associated with a wound without necessarily curing the wound or lessening in the growth or severity of a wound, skin irritation or skin inflammation. Compositions and formulations of the invention are particularly useful in the treatment of skin irritation, skin inflammation, and a wound associated with diabetes, such as a diabetic ulcer.

The invention provides antimicrobial compositions comprising charged cellulose nanofibrils dispersed in an aqueous solution having a dissolved oxygen content of at least 20 mg/L, preferably from 20 to 100 mg/L. The cellulose nanofibrils may have an increased surface charge due to their carboxylic acid content which contributes to their antimicrobial properties. In particular, the carboxylic acid content may be at least about 1000 μmol/g cellulose, preferably at least about 1400 μmol/g cellulose. The compositions are suitable for use in the treatment of wounds, in particular chronic wounds.

The invention provides an anti-PD-1 antibody comprising the complementary determining regions (CDRs) of pembrolizumab in combination with an antibody-drug conjugate that binds to tissue factor (TF) comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody comprising the CDRs of pembrolizumab and the antibody-drug conjugate that binds to TF comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.

The invention provides a “host-guest” supramolecular hydrogel. The hydrogel contains an AAm/NVP interpenetrating polymer network (IPN) with supramolecular cross-linkers assembled from β-lactam/adamantane-containing guest molecule with host polymeric cyclodextrin (PCD). An advantage of this hydrogel is that because of the molecular association of polymeric cyclodextrin and adamantane, the supramolecular hydrogels self-heal without any external stimuli after the hydrogels are severed. The invention also provides methods of making the hydrogel, methods of making the synthesis intermediates, and methods of diagnosis or treatment of β-lactamase-containing bacteria.